Plus Therapeutics Inc (PSTV)

Dec 17, 2024

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 - GlobeNewswire

Dec 17, 2024

Dec 17, 2024

Plus Therapeutics Reports Promising 88% Response Rate in Phase 1 Cancer Treatment Trial - StockTitan

Dec 17, 2024

Dec 16, 2024

PSTV stock touches 52-week low at $1.12 amid market challenges - Investing.com UK

Dec 16, 2024

Dec 11, 2024

Candel Therapeutics Stock Surges Over 100%Here's Why - Yahoo Finance

Dec 11, 2024

Dec 11, 2024

Candel Therapeutics Announces CAN-2409 Achieved Primary - GlobeNewswire

Dec 11, 2024

Dec 10, 2024

Plus Therapeutics (NASDAQ:PSTV) Price Target Lowered to $19.00 at Ascendiant Capital Markets - Defense World

Dec 10, 2024

Dec 09, 2024

Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash - The Manila Times

Dec 09, 2024

Dec 04, 2024

Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim - GlobeNewswire

Dec 04, 2024

Dec 04, 2024

Plus Therapeutics to Present Crucial Phase 1 Data for Novel Brain Cancer Treatment at Major Symposium - StockTitan

Dec 04, 2024

Dec 03, 2024

Plus Therapeutics Expands Strategic Agreement with Telix - GlobeNewswire

Dec 03, 2024

Dec 03, 2024

Plus Therapeutics Secures 5-Year Supply Deal for Key Cancer Treatment Radioisotope - StockTitan

Dec 03, 2024

Nov 30, 2024

HC Wainwright Reiterates Buy Rating for Plus Therapeutics (NASDAQ:PSTV) - Defense World

Nov 30, 2024

Nov 26, 2024

Plus Therapeutics shares hold price target, buy rating on positive study results - Investing.com

Nov 26, 2024

Nov 25, 2024

CNSide Diagnostics reports data from trial of CNSide CSF Assay in LM diagnosis - Medical Device Network

Nov 25, 2024

Nov 25, 2024

Plus Therapeutics' Cancer Drug Shows 93% Response Rate in Phase 1 Trial | PSTV Stock News - StockTitan

Nov 25, 2024

Nov 22, 2024

PSTVPLUS THERAPEUTICS, Inc. Latest Stock News & Market Updates - StockTitan

Nov 22, 2024

Nov 22, 2024

PSTV stock touches 52-week low at $1.14 amid market challenges - Investing.com UK

Nov 22, 2024

Nov 22, 2024

Plus Therapeutics to Present Positive FORESEE Clinical - GlobeNewswire

Nov 22, 2024

Nov 22, 2024

Plus Therapeutics' CNSide Trial Shows 90% Success in Cancer Treatment Decisions | PSTV Stock News - StockTitan

Nov 22, 2024

Nov 21, 2024

Plus Therapeutics to Present Multi-Institutional Experience - GlobeNewswire

Nov 21, 2024

Nov 21, 2024

Plus Therapeutics Reveals Breakthrough LM Cancer Biomarker Study with 88% Detection Rate | PSTV Stock News - StockTitan

Nov 21, 2024

Nov 19, 2024

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Short Interest Update - Defense World

Nov 19, 2024

Nov 18, 2024

Jones Trading cuts PSTV stock target, maintains Buy rating on Q3 earnings - Investing.com

Nov 18, 2024

Nov 18, 2024

Earnings call: Plus Therapeutics reports progress and financials for Q3 2024 - Investing.com

Nov 18, 2024

Nov 18, 2024

Contrasting Plus Therapeutics (NASDAQ:PSTV) and Inspira Technologies Oxy B.H.N. (NASDAQ:IINN) - Defense World

Nov 18, 2024

Nov 17, 2024

Plus Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 17, 2024

Nov 15, 2024

Plus: Q3 Earnings Snapshot - New Haven Register

Nov 15, 2024

Nov 15, 2024

Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Manila Times

Nov 15, 2024

Nov 15, 2024

Plus Therapeutics Inc (PSTV) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... - Yahoo Finance

Nov 15, 2024

Nov 14, 2024

Plus Therapeutics Advances Radiotherapeutics in Q3 2024 - TipRanks

Nov 14, 2024

Nov 14, 2024

Plus Therapeutics Advances Cancer Drug Pipeline, Reports $4.4M Grant Revenue in Q3 | PSTV Stock News - StockTitan

Nov 14, 2024

Nov 12, 2024

Organogenesis (ORGO) Tops Q3 Earnings and Revenue Estimates - Yahoo Finance

Nov 12, 2024

Nov 11, 2024

Leptomeningeal Metastases Clinical Trials 2024: FDA - openPR

Nov 11, 2024

Nov 09, 2024

Undercovered Dozen: Asbury Automotive, Globalstar, Northland Power, Aquestive Therapeutics - Seeking Alpha

Nov 09, 2024

Nov 08, 2024

Sitravatinib Plus Nivo-Ipi Appears Safe, Active in ccRCC - Cancer Therapy Advisor

Nov 08, 2024

Nov 07, 2024

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Nov 07, 2024

Nov 06, 2024

Plus Therapeutics partners with SpectronRx for cancer therapy - Investing.com India

Nov 06, 2024

Nov 06, 2024

Plus Therapeutics partners with SpectronRx for cancer therapy By Investing.com - Investing.com UK

Nov 06, 2024

Nov 06, 2024

Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership - GlobeNewswire

Nov 06, 2024

Nov 06, 2024

Plus Thera teams up with SpectronRx for radiotherapy production - The Pharma Letter

Nov 06, 2024

Nov 05, 2024

Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024 - GlobeNewswire

Nov 05, 2024

Nov 05, 2024

Plus Therapeutics (PSTV) Sets Q3 2024 Earnings Call for November 14 | PSTV Stock News - StockTitan

Nov 05, 2024

Nov 01, 2024

Plus Therapeutics granted extension by Nasdaq - Investing.com

Nov 01, 2024

Oct 29, 2024

Leptomeningeal Metastases Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca - The Globe and Mail

Oct 29, 2024

Oct 29, 2024

Plus Therapeutics Showcases Leptomeningeal Metastases - GlobeNewswire

Oct 29, 2024

Oct 27, 2024

Simulations Plus, Inc. (NASDAQ:SLP) Receives $56.00 Consensus Price Target from Analysts - Defense World

Oct 27, 2024

Oct 24, 2024

Metastatic Colorectal Cancer Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Daiichi Sankyo Company, Mirati Therapeutics, Apollomics - Barchart

Oct 24, 2024

Oct 21, 2024

Evaluating Immunotherapy as Systemic Therapy Plus RT in Early-Stage NSCLC - Cancer Network

Oct 21, 2024

Oct 21, 2024

Colorectal Cancer Pipeline Overview 2024: FDA Approvals and Key Companies involved by DelveInsight | Novartis, Pharma Oncology, Purple Biotech Ltd, Plus Therapeutics, Processa Pharma - The Globe and Mail

Oct 21, 2024